<DOC>
	<DOCNO>NCT02182219</DOCNO>
	<brief_summary>The primary objective study determine safety Maximum tolerate dose ( MTD ) BIBF 1120 combination therapy docetaxel prednisone patient hormone refractory prostate cancer . Secondary objective characterise pharmacokinetic profile BIBF 1120 docetaxel possible Pharmacokinetic ( PK ) interaction BIBF 1120 docetaxel obtain preliminary information anti-tumour activity .</brief_summary>
	<brief_title>Oral Treatment With BIBF 1120 Together With Docetaxel Prednisone Patients With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>1 . Patients histologicallyproven metastatic prostate adenocarcinoma 2 . Progression hormonal therapy 3 . Progressive disease follow : Increase PSA &gt; 5 ng/ml two occasion despite castrate level testosterone screen AND/OR Progressive measurable disease ( RECIST criterion ) AND/OR Progressive bone metastasis ( presence new lesion ( ) bone scan ) 4 . Life expectancy least three month 5 . ECOG performance status ≤ 2 6 . Patient write informed consent obtain prior trial procedure consistent ICHGCP ( International Conference Harmonization Good Clinical Practice ) guideline . 1 . Prior treatment hormone refractory prostate cancer ( HRPC ) include chemotherapy , biologic response modifier therapy , investigational drug 2 . Participation another clinical study within past four week start therapy concomitantly study 3 . Major injury surgery within past 4 week . Planned surgical procedure trial 4 . Brain metastases 5 . Radiotherapy superior 30 % medullar volume 6 . Other malignancy diagnose within past 5 year ( nonmelanomatous skin cancer ) 7 . Gastrointestinal abnormality would interfere intake absorption study drug , requirement intravenous alimentation , prior surgical procedure affect absorption , treatment peptic ulcer disease within last 6 month , active gastrointestinal bleeding unrelated cancer ( evidence either hematemesis , melena past 3 month without endoscopic document resolution ) , malabsorption syndrome 8 . Previous history stroke , angor pectoris , ischemic cardiomyopathy , cerebral ischemia , arteritis past 6 month 9 . Recent history hemorrhagic evolutive thrombotic event ( include transient ischemic attack ) past 6 month 10 . Patients require fulldose anticoagulation heparinization 11 . Absolute neutrophil count ( ANC ) &lt; 1,500/μl , platelet count &lt; 100,000/μl , hemoglobin &lt; 8 mg/dL 12 . Total bilirubin &gt; upper limit normal ( ULN ) ; alanine amino transferase ( ALT ) and/or aspartate amino transferase ( AST ) &gt; 1.5 X ULN 13 . Serum creatinine &gt; 1.5 mg/dL ( &gt; 132 μ mole/L , SI Unit equivalent ) 14 . Known suspect active alcohol drug abuse 15 . Patients unable comply protocol</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>